Investors in Puma Biotechnology, Inc. (PBYI) need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 20, 2025 $5 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could ...

Puma SE ( OTCPK:PUMSY ) ( OTCPK:PMMAF ) has a lot of tailwinds ahead as the company has large growth plans in the US market, and will benefit from their recent endorsements. Though their financial performance has been looking Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seekin ...

Puma SE ( PUMSY ) has gone down almost 50% this year. They have struggled with their profitability the past couple of years and investors has sent the company rocketing down. At the bright side, Puma is still growing its topline andHi, my name is Sander Pettersen Heio, I am from Norway. My primary focus is on foreign stocks, particularly within the Nordic market, where I analyze companies across various industries, from stable blue-chip firms to emerging market leaders. In addition to Nordic equities, I wri ...

Core Insights - The article emphasizes the importance of value investing and highlights Puma Biotechnology (PBYI) as a strong value stock opportunity [2][3][7] Company Metrics - Puma Biotechnology (PBYI) has a Zacks Rank of 2 (Buy) and a Value grade of A, indicating it is among the best value stocks currently available [3] - PBYI's PEG ratio is 1.38, significantly lower than the industry average of 3.07, suggesting it may be undervalued [4] - The company's P/B ratio stands at 2.06, compared to the industry average of 3.29, indicating a solid valuation relative to its book value [5] - PBYI's P/CF ratio is 4.22, which is attractive when compared to the industry's average of 13.37, further supporting the notion of undervaluation [6] Investment Outlook - The combination of PBYI's favorable metrics and strong earnings outlook positions it as a compelling value stock at this time [7]

Puma Biotechnology (PBYI) reported fourth-quarter 2024 adjusted earnings of 43 cents per share, which beat the Zacks Consensus Estimate of 14 cents. In the year-ago quarter, the company reported adjusted earnings of 31 cents per share.The above-adjusted earnings exclude the impact of stock-based compensation expense. Including the same, earnings per share were 39 cents compared with 26 cents in the year-ago quarter.For the fourth quarter, the company recorded a non-cash deferred tax income benefit of $7.1 m ...

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Mariann Ohanesian – Senior Director-Investor Relations Alan Auerbach – President and Chief Executive Officer Jeff Ludwig – Chief Commercial Officer Maximo Nougues – Chief Financial Officer Conference Call Participants Ed White – H.C. Wainwright Marc Frahm – TD Cowen Operator Good afternoon. My name is Darrell and I will be your conference call operator today. At this time, all participan ...

Puma Biotech (PBYI) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.31 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 207.14%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.35 per share when it actually produced earnings of $0.45, delivering a surprise of 28.57%.Over the last four quarte ...

Puma Biotechnology Earnings Call Commercial Update February 27, 2025 Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUMA BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 77-0683487 (State o ...

Exhibit 99.1 News Release Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results LOS ANGELES, Calif., Feb. 27, 2025 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2024 compared to the fourth quarter and full year 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Pum ...